Comparison of human Ether-à-go-go related gene screening assays based on ionworks quattro and thallium flux

Assay and Drug Development Technologies

Volumn 8, Issue 6, 2010, Pages 755-765

  Bridal, Terry R ^a   Margulis, Michael ^a   Wang, Xin ^a   Donio, Michael ^a   Sorota, Steve ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; ASTEMIZOLE; BEPRIDIL; CISAPRIDE; CLEMASTINE; DOFETILIDE; NEFAZODONE; PIMOZIDE; POTASSIUM; POTASSIUM CHANNEL HERG; QUINIDINE; TERFENADINE; THALLIUM; THIORIDAZINE; VERAPAMIL;

ARTICLE; CELL STRAIN HEK293; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IONWORKS QUATTRO; PATCH CLAMP; TRANSPORT KINETICS; VOLTAGE CLAMP;

CELLS, CULTURED; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUMINESCENT MEASUREMENTS; MEMBRANE POTENTIALS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; THALLIUM;

EID: 78650483557     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0267     Document Type: Article

References (25)

1. Sanguinetti MC, Jiang C, Curran ME, et al.: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
2. January CT, Gong Q, Zhou Z: Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2. J Cardiovasc Electrophysiol 2000;11:1413-1418.
3. Haverkamp W, Breithardt G, Camm AJ, et al.: The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47:219-233.
4. Allen MJ, Oliver SD, Newgreen MW, et al.: Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval. Br J Clin Pharmacol 2002;53:59-65.
5. Mitcheson J, Perry M, Stansfeld P, et al.: Structural determinants for high-affinity block of hERG potassium channels. Novartis Found Symp 2005;266:136-150; discussion 150-158.
6. Sanguinetti MC, Mitcheson JS: Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 2005;26: 119-124.
7. Hamill OP, Marty A, Neher E, etal.: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981;391:85-100.
8. Cheng CS, Alderman D, Kwash J, et al.: A high-throughput HERG potassium channel function assay: an old assay with a new look. Drug Dev Ind Pharm 2002;28:177-191.
9. Sorota S, Zhang XS, Margulis M, et al.: Characterization of a hERG screen using the lonWorks HT: comparison to a hERG rubidium efflux screen. Assay Drug Dev Technol 2005;3:47-57.
10. Wang K, Mcllvain B, Tseng E, et al.: Validation of an atomic absorption rubidium ion efflux assay for KCNQ/M-channels using the ion Channel Reader 8000. Assay Drug Dev Technol 2004;2:525-534.
11. Chiu PJ, Marcoe KF, Bounds SE, et al.: Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci 2004;95:311-319.
12. Diaz GJ, Daniell K, Leitza ST, et al.: The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: comparison of intact cell and membrane preparations and effects of altering [K+]o. J Pharmacol Toxicol Methods 2004;50:187-199.
13. Finlayson K, Turnbull L, January CT, et al.: [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol 2001;430:147-148.
14. Netzer R, Bischoff U, Ebneth A: HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Curr Opin Drug Discov Dev 2003;6:462-469.
15. Weaver CD, Harden D, Dworetzky SI, et al.: A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J Biomol Screen 2004;9:671-677.
16. Finkel A, Wittel A, Yang N, et al.: Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J Biomol Screen 2006;11:488-496.
17. Anumonwo JM, Horta J, Delmar M, et al.: Proton and zinc effects on HERG currents. Biophys J 1999;77:282-298.
18. Du X, Lu D, Daharsh ED, et al.: Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells. J Pharmacol Toxicol Methods 2006;54: 164-172.
19. Kiss L, Bennett PB, Uebele VN, et al.: High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug DevTechnol 2003; 1:127-135.
20. Bergstrom CA, Wassvik CM, Johansson K, et al.: Poorly soluble marketed drugs display solvation limited solubility. J Med Chem 2007;50:5858-5862.
21. Gao H, Yao L, Mathieu HW, et al.: In silico modeling of nonspecific binding to human liver microsomes. Drug Metab Dispos 2008;36:2130-2135.
22. Ploemen JP, Kelder J, Hafmans T, et al.: Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp Toxicol Pathol 2004;55:347-355.
23. Su Z, Limberis J, Souers A, et al.: Electrophysiologic characterization of a novel hERG channel activator. Biochem Pharmacol 2009;77:1383-1390.
24. Zhou Z, Gong Q, Ye B, et al.: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998;74:230-241.
25. Yang T, Roden DM: Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93:407-411.